Biohaven Rebounds With FDA Review Date for Rare Disease Drug
FDA accepts Biohaven's Vyglxia NDA resubmission for SCA with a Q1 2027 goal date, planning an advisory committee review.
Share
Why It Matters
Biohaven resubmitted its rare disease medicine to the FDA for review. The FDA said they will decide by early 2027, which is progress.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.